News
CRITICARE, February 15-19, Pune, India
January 24 2012
Conference on Continuous Renal Replacement Therapies (CRRT), February 12-15, San Diego, USA
January 24 2012
MEDLAB, Arab Health, January 23-26, Dubai, UAE
January 16 2012
An addition to the Obesity and Type 2 Diabetes antibody portfolio
December 22 2011
Better kidney markers ahead?
December 05 2011
New NGAL.com website launched
November 24 2011
MEDICA, November 16-19, Düsseldorf, Germany
October 26 2011
ASN Kidney Week, November 8-13, Pennsylvania, Philadelphia, USA
October 20 2011
ESICM 2011, October 1-5, Berlin, Germany
September 06 2011
AACC Clinical Lab Expo, July 24-28, Atlanta
July 04 2011
Further expansion of our GLP-1 portfolio: Anti-GLP-1 (Non-amidated (-Arg-Gly) C-terminal specific) antibody
June 10 2009 by Ana Belén Enfedaque Buisán
BioPorto Diagnostics is pleased to announce the launch of a new monoclonal antibody ABS 046-03. The new antibody ABS 046-03 recognizes the C-terminus of non-amidated (-Arg-Gly) GLP-1 and shows a low level of cross-reactivity with C-terminally amidated GLP-1.
The active forms of GLP-1 are potent stimulators of glucose-dependent insulin secretion and GLP-1 receptor agonists are strong drug candidates for the treatment of type 2 diabetes. BioPorto Diagnostics’ GLP-1 antibody portfolio provides useful tools for physiological and pharmaceutical research into the therapy of type 2 diabetes, and, as GLP-1 is also involved in the regulation of food intake, in developing treatments for obesity.
The launch of this new antibody brings BioPorto Diagnostics a step closer to being able to offer a complete GLP-1 antibody portfolio, which currently includes unique antibodies for several different GLP-1 forms and related targets such as Exendin-4.
BioPorto Diagnostics is launching this antibody as a part of the AntibodyShop portfolio and expects to expand the GLP-1 group of antibodies even further in the future.
